title: Case-matched comparison of vitrectomy, peripheral retinal endolaser, and endocyclophotocoagulation versus standard care in neovascular glaucoma.
abstract: OBJECTIVE
  To evaluate the efficacy of combination pars plana vitrectomy, endoscopic peripheral panretinal photocoagulation, and endocyclophotocoagulation (ECP) as compared with standard care in patients with neovascular glaucoma.
  
  
  METHODS
  This age-matched case-controlled retrospective series of 54 eyes compared the clinical outcomes between a consecutive series of combination pars plana vitrectomy/panretinal photocoagulation/ECP (n = 27) versus the current standard of care (n = 27) for patients with neovascular glaucoma. "Standard" treatments for patients with neovascular glaucoma include panretinal photocoagulation, intravitreal bevacizumab, filtration surgery, pars plana vitrectomy, and Ahmed valve placement.
  
  
  RESULTS
  After 1 year, mean intraocular pressure reduced from 40.7 ± 12.40 mmHg preoperatively to 12.3 ± 4.84 mmHg (P < 0.001) in the ECP group and from 34.7 ± 12.38 mmHg to 23.2 ± 12.34 mmHg in the control group (P = 0.002). Compared with controls, the mean drop in intraocular pressure in the ECP group was significantly greater at all postoperative visits. Logarithm of the minimal angle of resolution visual acuity outcomes were similar in both groups. There were 2 cases (7.4%) of postoperative phthisis bulbi in each group.
  
  
  CONCLUSIONS
  Endoscopic pars plana vitrectomy, panretinal photocoagulation, and ECP seem to control intraocular pressure to a greater extent than standard glaucoma treatments in patients with neovascular glaucoma. In this aged-matched comparative case series, there was no significant difference between the two treatments' effects on visual acuity.
authors.affiliation: *Retina Service, Division of Ophthalmology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; †University of California, San Diego School of Medicine, San Diego, California; ‡College of Human Medicine, Michigan State University, East Lansing, Michigan; §Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts; ¶Department of Ophthalmology, Faculty of Medicine, Assiut University, Assiut, Egypt; and **Albert Einstein College of Medicine, New York, New York.
authors.forename: Kyle V
authors.initials: KV
authors.lastname: Marra
authors.forename: Sushant
authors.initials: S
authors.lastname: Wagley
authors.forename: Ahmed
authors.initials: A
authors.lastname: Omar
authors.forename: Taiga
authors.initials: T
authors.lastname: Kinoshita
authors.forename: Kyle D
authors.initials: KD
authors.lastname: Kovacs
authors.forename: Paolo
authors.initials: P
authors.lastname: Silva
authors.forename: Mark C
authors.initials: MC
authors.lastname: Kuperwaser
authors.forename: Jorge G
authors.initials: JG
authors.lastname: Arroyo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D016022:Case-Control Studies; D002924:Ciliary Body / Q000601:surgery*; D005260:Female; D018463:Filtering Surgery; D020327:Glaucoma Drainage Implants; D015355:Glaucoma, Neovascular / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D058449:Intravitreal Injections; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000601:surgery*; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014821:Vitrectomy
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab